Warfarin Aspirin Recurrent Stroke Study (WARSS)

Introduction

Design:

Double-blind, randomized trial

2206 ischemic stroke patients at 47 centers

aspirin 325 mg QD vs warfarin (target INR 1.4-2.8)

primary endpoint: recurrent ischemic stroke or death

Results:

Hazard ratios (HR) favor aspirin:

stroke or death: HR = 1.13

hemorrhage: HR = 1.15

More general terms

• clinical trial